TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05234177: Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Sponsor: Tempus AI · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$4,389,000

Rescue Site Savings

+$2,910,600

Unlock Full NCT05234177 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05234177 Rescue Dossier →